Although single-target inhibitors of either the PI3K/Akt/mTOR pathway or HDACs would be good drug candidates for cancer therapy, their demonstrated efficacies are limited due to their unfavorable pharmaceutical activities, toxicity, and crossover inhibition of other lipid and protein kinases [17]. Here, WEE1 is linked to cancer.